2 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Progressive Disease: new trials by email Literature Review of Progressive Disease trials Research Report on Progressive Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 |
Disease Progression (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1)
Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bone Marrow Diseases (1) · Chronic Disease (1) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Leukemia (1) · Leukemia, B-Cell (1)
Cyclophosphamide (1) · Hydroxychloroquine (1) · devimistat (1) · fludarabine (1)
M.D. Anderson Cancer Center (1) · Wake Forest University Health Sciences (1)
United States (2)
Bayard Powell, MD (1) · Jin S Im (1)
P30CA012197 (1), P30CA016672 (1)